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Abstract
Chagas disease is caused by infection with the intracellular protozoan parasite Trypanosoma cruzi. At present, nifurtimox
and benznidazole, both compounds developed empirically over four decades ago, represent the chemotherapeutic arsenal
for treating this highly neglected disease. However, both drugs present variable efficacy depending on the geographical
area and the occurrence of natural resistance, and are poorly effective against the later chronic stage. As a part of a search
for new therapeutic opportunities to treat chagasic patients, pre-clinical studies were performed to characterize the activity
of a novel arylimidamide (AIA - DB1831 (hydrochloride salt) and DB1965 (mesylate salt)) against T.cruzi. These AIAs displayed
a high trypanocidal effect in vitro against both relevant forms in mammalian hosts, exhibiting a high selectivity index and a
very high efficacy (IC50 value/48 h of 5–40 nM) against intracellular parasites. DB1965 shows high activity in vivo in acute
experimental models (mouse) of T.cruzi, showing a similar effect to benznidazole (Bz) when compared under a scheme of 10
daily consecutive doses with 12.5 mg/kg. Although no parasitological cure was observed after treating with 20 daily
consecutive doses, a combined dosage of DB1965 (5 mg/kg) with Bz (50 mg/kg) resulted in parasitaemia clearance and
100% animal survival. In summary, our present data confirmed that aryimidamides represent promising new chemical
entities against T.cruzi in therapeutic schemes using the AIA alone or in combination with other drugs, like benznidazole.
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Introduction
Chagas disease is a neglected illness caused by the obligatory
intracellular protozoan Trypanosoma cruzi, extending from Central
to South America [1]. This disease has two consecutive clinical
phases: acute phase, in which the parasite dissemination can be
seen directly on examination of blood. After few weeks, the
parasitism burden is controlled by host immune response and the
disease moves to the chronic stage. Most of the infected individuals
do not present recognizable pathological markers, however, after a
long period (about 10–30 years) of clinical latency called the
indeterminate form, some of them show disease manifestations,
mainly associated with cardiac and/or digestive disturbances [1,2].
Benzinidazole (Bz) and Nifurtimox (NF), introduced into clinical
therapy about 40 years ago, cause many side effects, besides
displaying limited efficacy, especially in later chronic phase [2,3].
Also, several reports have demonstrated that some strains are
refractory to treatment [4,5]. Presently, posaconazole, a new anti-
fungal agent that has been effective against T.cruzi in vitro and in
vivo assays, has moved to clinical trials, however, even if effective,
its use may be limited due to its high costs [6,7].
Aromatic amidines (AD) are DNA minor groove binders that
recognize enriched AT sequences [8]. In addition to showing high
anti-parasitic activity against fungi, amoeba, bacteria and
especially protozoan parasites, some of these cationic compounds,
such as pentamidine have been used to treat neglected diseases
such as African trypanosomiasis and leishmaniasis. Despite having
unfavorable characteristics like poor oral solubility and undesir-
able side effects [9], the broad activity of these compounds has
stimulated further screening of new analogs and prodrugs [6]. One
class of analogues that have different physiochemical properties
are the arylimidamides (AIAs) which have showed high efficacy in
vitro and in vivo against T.cruzi [10–14]. Studies in vivo with the AIA
DB766 demonstrated a reduction in the parasite load levels in the
blood and cardiac tissue with similar trypanocidal activity as that
of Bz in a mouse model of acute T.cruzi infection using both Y and
Colombian strains [11,15]. This AIA lead to the recovery of
electrocardiographic alterations in addition to reducing hepatic
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excellent activity of DB766 motivated the design and synthesis of
novel structurally related compounds including the AIA, DB1831
(hydrochloride salt) and its mesylate salt form (DB1965) for which
in vitro and in vivo studies are reported here with the goal of
identifying novel anti-T. cruzi candidates for possible future
alternative therapies for Chagas disease.
Materials and Methods
Compounds
The synthesis of DB1831 and DB1965: (Figure 1) was performed
as reported for other analogues ([10,16] - and will be reported
elsewhere). Benznidazole (Bz, Laborato ´rio Farmace ˆutico do
Estado de Pernambuco - LAFEPE, Brazil) was used as reference
drug [11]. Stock solutions of the compounds (5 mM) were
prepared in dimethyl sulfoxide (DMSO) and fresh final solvent
concentration in the assays never exceeded 0.6%, which is not
toxic for both parasites and mammalian cells. For in vivo studies, a
stock solution of DB1965 was first prepared in DMSO and then
diluted using distilled and sterile water. The final concentration of
DMSO never exceeded 10%, which do not provide detectable
mice toxicity [11].
Cell cultures
For both drug toxicity and infection assays, primary cultures of
cardiac cells (CM) were obtained as reported [17]. The cultures
were sustained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% horse serum, 5% fetal bovine serum
(FCS), 2.5 mM CaCl2, 1 mM L-glutamine, and 2% chicken
embryo extract. Cell cultures were maintained at 37uCi na n
atmosphere of 5% CO2 and air, and assays were run at least three
times in duplicates.
Parasites
Y strain of Trypanosoma cruzi (lineage type II) was used
throughout the experiments. Bloodstream trypomastigotes (BT)
were harvested by heart puncture from T. cruzi-infected Swiss mice
at the parasitaemia peak day [17]. Intracellular amastigotes lodged
within cardiac cell cultures were employed as reported [11].
In Vitro Cytotoxicity assays
In order to rule out toxic effects of the compounds against
mammalian host cells, uninfected cardiac cultures were incubated
for 24 and 48 h at 37uC in the presence or absence of each
compound diluted in DMEM. The CM morphology and
spontaneous contractibility were evaluated by light microscopy.
The cell death rates were measured by MTT (3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) colorimetric as-
say [18]. The absorbance was measured at a wavelength of
490 nm with a spectrophotometer (VersaMax tunable microplate
reader; Molecular Devices), which allows for the determination of
LC50 (compound concentration that reduces 50% of cellular
viability).
Trypanocidal analysis
BT were incubated at 37uC for 24 h in the presence of
increasing non-toxic concentrations of the tested compounds
diluted in in RPMI 1640 medium (Roswell Park Memorial
Institute- Sigma Aldrich – USA) supplemented with 5% fetal
bovine serum. Alternatively, according to protocols already
established by our group [11], experiments were also performed
with BT for 24 h using serial dilutions of the tested compound at
4uC in the presence or absence of freshly isolated mouse blood
(96%). Death rates were determined by light microscopy through
direct quantification of the number of live parasites using a
Neubauer chamber, and the IC50 (drug concentration that reduces
50% of the number of the treated parasites) calculated. For the
analysis of the effect against intracellular amastigotes, after 24 h of
parasite-host cell interaction (10:1 parasite:CM ratio), the infected
cultures were washed to remove free parasites and then incubated
for another 48 h with increasing but non-toxic doses of the test
compounds. CM were maintained at 37uC in an atmosphere of
5% CO2 and air and the medium replaced every 24 h. Then,
untreated and treated infected CM were fixed and stained with
Giemsa solution and the mean number of infected host cells and of
parasites per infected cells scored as reported [12]. Only
characteristic parasite nuclei and kinetoplasts were counted as
surviving parasites since irregular structures could mean parasites
undergoing death. The drug activity was estimated by calculating
the infection index (II - percentage of infected cells times the
average number of intracellular amastigotes per infected host cell)
[12]. All assays in vitro were run at least twice in duplicates.
Mice acute toxicity
NOAEL (No Observed Adverse Effect Level) was evaluated
using male and female Swiss Webster mice (20–23 g). On day 1,
one female and one male mice were treated with DB1965 under
two therapeutic schemes: (i) injection via intraperitoneal (ip) every
2 h, with increasing doses, starting at 25 mg/kg up to 400 mg/kg
and (ii) administration by ip or per oral (p.o) at doses ranging 25–
400 mg/kg [11]. Additionally, male mice (n=5 for each group)
were treated with 20 daily consecutive doses with vehicle (only
DMSO and water), 5 mg/kg DB1965 (ip), 50 mg/kg Bz (p.o) and
with both combined compounds (5 mg/kg DB1965 ip+50 mg/kg
Bz p.o). In all schemes, mice were inspected for toxic and sub-toxic
symptoms according to OECD guidelines (Organization for
Economic Co-operation and Development). Forty-eight hours
after compound injection, the NOAEL values were determined
[11].
Mice infection and treatment schemes
Male Swiss mice were obtained from the Fundac ¸a ˜o Oswaldo
Cruz (FIOCRUZ) animal facilities (Rio de Janeiro, Brazil). Mice
were housed at maximum 8 per cage and kept in a conventional
room at 20–24uC under a 12/12 h light/dark cycle. The animals
were provided with sterilized water and chow ad libitum. Infection
was performed by ip injection of 10
4 bloodstream trypomastigotes.
The animals (18–21 g) were divided into the following groups (at
least five mice per group): uninfected (non-infected and non-
treated); untreated (infected with T. cruzi but treated only with
vehicle); and treated (infected and treated - ip and p.o - with 12.5
Figure 1. Chemical structure of the compounds.
doi:10.1371/journal.pone.0030356.g001
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dazole). For DB1965 treatment, mice received 0.1 mL ip injection
or 0.2 mL oral dose, starting at the 5 dpi followed by (i) for 5, (ii)
10 or (iii) 20 consecutive daily doses. For Bz treatment, infected
mice received 0.2 mL oral dose (gavage) following the same
therapeutic schemes as above described. Thirty days after
compound administration, about 1000 mL of blood were collected
from the heart of anesthetized mice and then 500, 200 and 250 mL
were used for PCR, hemoculture and biochemical analysis,
respectively [11].
Parasitaemia, mortality rates and ponderal curve analysis
Parasitaemia was individually checked by direct microscopic
counting of parasites in 5 mL of blood, as described before [19]. At
7, 14, 21 and 28 dpi body weight was evaluated and the data
represent the variation between the different mouse groups
measured at 30 days post treatment. Mortality checked daily until
30 days post treatment and expressed as percentage of cumulative
mortality (%CM) [11].
Electrocardiography (ECG)
ECG recording and analysis were performed in uninfected,
acutely T. cruzi-infected mice (after 30 days post treatment) subjected
or not to DB1965 and Bz therapy, as previously described [11].
Briefly, mice were placed under stable sedation with diazepan
(20 mg/kg, ip), fixed in the supine position, and eight-lead ECG was
recorded from18-gauge needle electrodes subcutaneously implanted
in each limb and two electrodes at precordial positions lead II. The
electrocardiographic (ECG) tracings were obtained with a standard
lead (dipolar lead DII), recording with amplitude set to give 2 mV/
1 s. ECG was recorded by using band-pass filtering (Bio Amp - AD
Instruments, Hastings, United Kingdom) between 0.1 and 100 Hz.
Supplementary amplification and analog-digital conversion was
performed with a Powerlab 16S instrument (AD Instruments,
Hastings). Digital recordings (16 bit, 4 kHz/channel) were analyzed
with the Scope (version v3.6.10) program (AD Instruments). The
signal-averaged ECG (SAECG) was calculated by using the mouse
SAECG extension (version 1.2) program (AD Instruments) and a
template-matching algorithm. ECG parameters were evaluated
using the following standard criteria: (i) the heart rate was monitored
by beats/minute, and (ii) the variation at P wave and PQ, QRS and
QT intervals were measured in milliseconds (ms).
Blood pressure
Before evaluation of blood pressure, mice were kept in their
cages for at least seven days to allow for acclimatization to the
laboratory conditions, and a tail sphygmomanometer was fitted for
three consecutive readings until stabilization was observed. Blood
pressure was individually recorded at 30 days post treatment using
an LE 5001 Pressure meterH (PanLab Instruments, Barcelona -
Spain), evaluating caudal artery pressure in non-sedated animals.
Values of systolic (SP), diastolic (DP) and the mean (MP) pressure
were calculated as indicated by the manufacturer [20].
Biochemical analysis
The levels of alanino Aminotransferase (ALT), urea and
creatine kinase (CK) were determined directly in the blood using the
Reflotron system (Roche Diagnostics, F. Hoffmann-La Roche Ltd.; Basel,
Switzerland) as previously reported [11].
Histopathology analysis
At 30 days post treatment, hearts were removed, cut
longitudinally, rinsed in ice-cold PBS, and fixed in Millonig-
Rosman solution (10% formaldehyde in phosphate-buffered
saline). The tissues were dehydrated and embedded in paraffin.
Sections (3 mm) stained by routine hematoxylin-eosin were
analyzed by light microscopy. The number of amastigote nests
and of inflammatory infiltrates (more than 10 mononuclear cells)
was determined in at least 30 fields (total magnification, 406) for
each slide, from at least three mice per group with three sections
from each mouse [21].
Cure assessment
As reported [11,15], cure criteria were based on three
parasitological methods: (i) parasitaemia negativation observed
by light microscopy, (ii) Polymerase Chain Reaction (PCR) and (iii)
hemoculture assays. Animals presenting negative results for all
tests were considered cured.
The DNA extraction and PCR protocols were adapted and
standardized for rodent samples as previously reported
[11,15,22,23]. Briefly, 500 mL blood was diluted in 1:3 volume
of guanidine solution (guanidine-HCl 6 M/EDTA 0.2 M), and
heated for 90 seconds in boiling water in order to cleave the
parasite kDNA network [15,22,23]. The PCR was performed
using the primers: (59AAATAATGTACGGG(T/G)GAGATG-
CATGA39) and (59GGTTCGATTGGGGTTGGTGTAATA-
TA39), which amplify a 330 bp sequence from the minicircles
kinetoplast DNA (aprox. 120,000 copies/parasite), as previously
described [23]. The PCR was carried out using a GeneAmpH
PCR Sytem 9700 (Applied Biosystems) as follows: one step at 94uC
for 3 min (to activate the Taq platinum DNA polymerase), 2 cycles
at 98uC for 1 min and 64uC for 2 min, 38 cycles at 94uC for 1 min
and 64uC for 1 min, followed by a final extension at 72uC for
10 min. The amplification products were detected by 1.5%
agarose gel electrophoresis following staining with ethidium
bromide staining (5 mg/mL). For hemoculture, 200 mL of blood
was added to 5 mL LIT medium and incubated at 28uC for 30
days, being weekly examined by light microscopy to detect
epimastigote forms [24]. Only negative parasitaemia and hemo-
cultive samples were further screened by PCR analysis [11,15].
Statistical analysis
Statistical analysis was performed individually for each assay
using a variance (ANOVA) program with the level of significance
set at p#0.05. The data are representative of 2–4 experiments run
in duplicate.
Ethics
All procedures were carried out in accordance with the
guidelines established by the FIOCRUZ Committee of Ethics
for the Use of Animals (CEUA 0028/09).
Results
DB1831 displayed a dose-dependent trypanocidal activity
against bloodstream trypomastigotes, reaching after 24 h/37uC,
an IC50 value of 20 nM (Table 1). With the goal of possible
application in blood bank prophylaxis, BT were assayed at 4uCi n
the presence or absence of blood constituents. The data at 4uC
showed that DB1831 retained a high efficacy (IC50 values of 80
and 24 nM with or without mice blood, respectively) as compared
to reference drug (IC50.250.000 nM) (Table 1). Afterwards,
toxicity aspects of DB1831 were studied in vitro using cardiomy-
ocytes cultures. Treatment at 37uC for 24 and 48 h resulted in loss
of cellular viability only when higher doses were employed,
showing 50% lethal concentration of 32 and 15 mM, respectively.
Efficacy of Novel Arylimidamide against T. cruzi
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using nontoxic doses (up to 10.6 mM). DB1831 also reduced both
the percentage of infected cells and the mean number of parasites
per infected cells, revealed by the infection index determination,
which exhibited an outstanding IC50=5 nM after 48 h of
treatment (Table 1). Excellent SI values (1600 and 2900 for BT
and intracellular parasites) were found (Table 1). However, due to
the poor solubility of DB1831, a methanesulfonic acid salt
(DB1965) was obtained for further in vivo analysis.
Before assaying DB1965 in an experimental model of an acute
T.cruzi infection, its trypanocidal effect was verified against
trypomastigotes and intracellular forms. After 24 h, DB1965
demonstrated high efficacy, showing an IC50=31nM at 37uC,
with outstanding activity at 4uC in the presence of blood (Table 1).
DB1965 was also very effective on intracellular forms with
IC50=40 nM (Table 1). These data confirmed the high activity
and selectivity of both AIAs (DB1831 and DB1965) when
compared with Bz (Table 1).
Next, two schemes of acute toxicity studies were conducted
using DB1965 aiming to determine the NOAEL values. In the first
set, when DB1965 was given to female mice by different routes (ip
and p.o), considerable toxic side effects like ataxia and tremors
(gross pathology also showed hemorrhagic intestinal signs) were
found with doses $200 mg/Kg administrated by ip, inducing
animal death at 400 mg/Kg dose (data not shown). However, oral
administration of DB1965 neither lead to mortality nor revealed
significant side effects when followed up to 48 h after DB1965
injection (up to 400 mg/kg) (data not shown). In a second scheme
of acute toxicity evaluation, female and male mice were injected ip
with increasing doses of DB1965. The data confirmed previous
results, showing that both animals (female and male) died at the
dose of 400 mg/kg, presenting side effect at doses $30 mg/kg
(Table 2).
Next, efficacy of DB1965 was assayed in Swiss male mice
inoculated with 10
4 bloodstream parasites using three different
treatment schemes employing doses that did not cause mortality in
the acute toxicity studies. Only those mice that presented positive
parasitaemia were used in the following studies.
In the first scheme of treatment (Scheme 1), DB1965 was
administered at 5 to 9 dpi (5 daily consecutive doses) using 12.5
and 25 mg/kg/day, and 100 mg/kg/day by ip and p.o routes,
respectively. As expected for this experimental mouse model of
T.cruzi acute infection using Y strain, infected and untreated mice
(untreated group) presented high parasitaemia levels, peaking at
8 dpi (Fig. 2A). When DB1965 was administrated via ip a
reduction of 93 and 99% in parasitaemia levels was observed using
12.5 and 25 mg/kg/day dose, respectively.
On the other hand, gavage administration of DB1965 and Bz
resulted in 51 and 100% of decrease in parasitaemia levels,
respectively (Fig. 2A).
Biochemical analysis performed at 30 days post treatment
showed that only minor differences could be noted between the
different mice groups. Regarding ALT measurements a significant
increase (p=0.02) was found when infected but untreated animals
were compared to uninfected group. However, Bz (p=0.18), 12.5
(p=0.33) and 25 mg/kg (p=0.80) DB1965 did not show any
Table 1. Trypanocidal effect of Arylimidamides and Benznidazole against T. cruzi (Y strain).
Compounds Bloodstream Trypomastigotes (24 h) Intracellular Parasites (48 h)
46C3 7 6C
Blood RPMI
IC50 (mM) IC50 (mM) IC50 (mM) SI IC50 (mM) SI
DB1831 0.0860.04 0.02460.004 0.0260 1600 0.00560.001 2900
DB1965 0.00860.00 0.00460.003 0.03160.01 342 0.0460.01 265
Bz .250 .250 12.9461.93 .77 2.861.96 .360
The activity of the compounds against bloodstream trypomastigotes (BT) and intracellular parasites was evaluated during their incubation at 37uC and at 4uC for 24 h
and 48 h.
All assays were run at least two times in duplicate.
IC50 values=Compound concentration that reduces the number of parasites by 50%.
SI*=selectivity index corresponds to the ratio LC50/IC50 – For BT and intracellular parasites calculated on LC50 values of 24 and 48 h of incubation at 37uC, respectively.
Bz=Benznidazole.
doi:10.1371/journal.pone.0030356.t001
Table 2. Acute toxicity analysis – Escalating doses using a single mice (starting at 20 mg/kg up to 400 mg/kg DB1965 – ip – using
0.1 mL final volume per mice): Swiss male and female mice (20–23 g).
20 mg/kg 30 mg/kg 50 mg/kg 100 mg/kg 200 mg/kg 400 mg/kg NOAEL
Male No detectable
effect
Reversible tremor, abdominal
contractions and ruffled fur
Reversible
abdominal
contractions
Reversible
abdominal
contractions
Reversible
abdominal
contractions
Reversible abdominal
contractions and death
20 mg/kg
Female No detectable
effect
Reversible tremor, abdominal
contractions and ruffled fur
Reversible
abdominal
contractions
Reversible
abdominal
contractions
Reversible
abdominal
contractions
Reversible abdominal
contractions and death
20 mg/kg
NOAEL (No observed adverse effect level).
All assays were run at least two times.
doi:10.1371/journal.pone.0030356.t002
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(Table 3). When urea levels were analyzed, although no major
alteration (p=0.14) was noticed among uninfected and infected
but untreated mice, the administration of 12.5 mg/kg DB1965
displayed a statistical difference (p=0.03) as compared to those
infected mice that did not receive any treatment (Table 3). On the
other hand, neither Bz (p=0.16) and 25 mg/kg DB1965 (p=0.10)
showed considerable alteration urea plasma levels as compared to
those infected but untreated animals (Table 3).
The analysis of parasitological cure (by hemocultive and PCR)
demonstrated that no cure was achieved in both Bz and DB1965
treated mice (Table 4). Also, as the ip dose of 12.5 mg/kg of the
AIA achieved 100% of animal survival (Fig. 2B), this later dose was
selected for the second round of assays, using 10 daily consecutive
doses (at 5 dpi for 10 dpi).
The data showed that quite similar parasitaemia control was
reached using Bz (99.8%) and DB1965 (97%) (Fig. 2C). Although
both DB1965 and Bz were effective in protecting against animal
mortality, resulting in about 90 and 100% of survival, respectively
(Fig. 2D), neither were able to produce parasitological cure of the
animals (Table 4). Because some reversible side effects like
hyperactivity was noted for the DB1965 group at the end of the
treatment (after the 7th day of DB1965 administration), and
aiming to find an alternative scheme of therapy using this highly
active AIA, a combined treatment of DB1965 (5 mg/kg/day) and
Bz (50 mg/kg/day) was next employed, under a scheme of 20
daily consecutive doses.
Our data showed that all treated mice (treated with each
compound alone and with Bz+DB1965) presented 100% of
survival (Fig. 2F). These treated mice also displayed a suppression
Figure 2. Treatment of T. cruzi-infected mice (10
4 Y strain/mice) with DB1965. The activity of 5 (E–F), 12.5 and 25 (A–D) mg/Kg/day of
DB1965 (ip) and 100 mg/kg/day DB1965 via p.o (A–B) is presented. As reference drug, 50 and 100 mg/Kg/day benznidazole (by p.o) was also
evaluated using similar therapeutic schemes at the 5–9 dpi (A–B), 5–14 dpi (C–D) and 5–24 dpi (E–F). Parasitaemia curves (A, C and E) and percentage
of cumulative mortality (B, D and F) are shown. All assays were run at least two times.
doi:10.1371/journal.pone.0030356.g002
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of decrease after Bz, Bz+DB1965 and DB1965 administration
(Fig. 2E). The ponderal curve shows that neither DB1965 alone
nor in combination with Bz was able to lead to recovery of the
mice weight loss induced by the parasite infection (data not
shown). The analysis of organ weight revealed that although
parasite infection induced an increase in all studied organs (heart,
spleen, liver and kidney), only statistically significant differences
were observed in liver weight (p=0.022) from infected and
untreated mice as compared to uninfected animal groups (data not
shown). As compared to untreated mice, all treated groups – Bz
(p=0.029), DB1965 (p=0.013) and Bz+DB 1965 (p=0.022) lead
to a return of heart weight to pre-infection values (data not shown).
Regarding liver, only the combined therapy partially restored
(p=0.03) the organ weight increase due to parasite infection (data
not shown).
ECG analysis showed a statistically significant bradycardia
(p=0.02) in infected and untreated mice group as already reported
in this experimental model of acute T.cruzi infection [21].
However, none of the therapeutic groups were able to avoid this
cardiac electric alteration (data not shown). No statistically
significant differences were found in blood pressure analysis
among all studied groups (data not shown). Also, among all
treatment regimens, only 1 out of 06 surviving mice from the
DB1965 treated groups (12.5 mg dose – scheme 1 and
DB1965+Bz – scheme 3) displayed negative hemocultive.
However, both animals displayed positive PCR, showing no
parasitological cure (Table 4).
Table 3. Biochemical analysis of T.cruzi-infected mice treated or not by DB1965 and Benznidazole.
Urea (mg/dL) ALT (U/liter) CK(U/liter)
Reference Values [references 11,31] 52692 2 655 0 2 6507
Uninfected 5368.4 3365.6 3836223
Infected and untreated 4466.7 (p=0.14) 4565( p=0.02) 5956622 (p=0.54)
25 mg/kg DB1965 ip 59611(p=0.1) 43614 (p=0.8) 208673 (p=0.34)
12.5 mg/kg DB1965 ip 5869( p=0.03) 4067.6 (p=0.33) 357661 (p=0.46)
100 mg/kg Bz p.o 56612 (p=0.16) 35611 (p=0.18) 2966122 (p=0.45)
All assays were run at least two times and the data represent Mean 6SD.
ALT=alanino Aminotransferase.
CK=creatine kinase.
Bz=Benznidazole.
doi:10.1371/journal.pone.0030356.t003
Table 4. Cure assessment of DB1965 combined or not with benznidazole (Bz) in murine model of acute T. cruzi-infection
1.
Experimental groups
Therapy
route
1,2 and 3
Number of surviving/
total number of animals Assays performed after 30 days post treatment
Number of negative
hemoculture samples/
number of mice
Number of negative
blood PCR samples/
number of mice
Scheme 1
(5 consecutive daily doses)
Untreated - 3/5 0/3 -
Bz 100 mg/kg p.o 4/4 0/4 nd
DB1965 100 mg/kg p.o 5/6 0/5 nd
DB1965 100 mg/kg ip 3/5 0/3 nd
DB1965 12.5 mg/kg ip 6/6 1/6 0/1
Scheme 2
(10 consecutive daily doses)
Untreated - 2/7 0/2 nd
Bz 100 mg/kg p.o 5/5 0/5 nd
DB1965 12.5 mg/kg ip 7/8 0/7 nd
Scheme 3
(20 consecutive daily doses)
Untreated - 2/6 0/2 nd
Bz 50 mg/kg p.o 6/6 0/6 nd
DB1965 5 mg/kg ip 6/6 0/6 nd
DB1965 5 mg/kg+Bz 50 mg/kg ip+p.o 6/6 1/6 0/1
1Swiss male mice weight 20 to 24 g inoculated with 10
4 blood trypomastigotes (Y strain).
Treatment was initiated at 5u dpi followed by different schemes of treatment (up to 20 consecutive daily doses). All assays were run at least twice.
2Intraperitoneal – ip.
3per oral – p.o.
Nd=not done.
doi:10.1371/journal.pone.0030356.t004
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be found in the cardiac tissues among the different experimental
infected mice groups (data not shown). Aiming to explore the
potential cumulative toxicity after a long-term treatment, different
clinical and biochemical parameters were evaluated after 20 daily
consecutive doses of each compound. Our data showed that all
groups presented 100% survival, and that except for the analysis of
body weight (variation between mouse groups measured after the
end of the treatment), no major toxic side effects could be observed.
We found that mice injected with vehicle alone reached 49611% of
body weight gain, while Bz-treated animals showed 25611%
significant decrease (p=0.006) (data not shown).
Discussion
AIAs belong to a class of amidine compounds with high
trypanocidal activity in vitro [14] and in vivo [11] and the present
study confirmed and extended previous observations of their
properties.
The evaluation of both in vitro and in vivo effects of DB1831/
DB1965 against T.cruzi infection showed their excellent efficacy
against bloodstream trypomastigotes and intracellular amastigotes,
with high selectivity indexes, confirming previous data using other
AIAs [11,12,14]. DB1831 exhibited an outstanding effect against
intracellular parasites (IC50=5 nM), which is about 560-fold
higher than Bz. The high activity of DB1831 and DB1965 was
maintained when BT were incubated at different temperatures
and with blood mice, also confirming the promising activity of
AIAs for a blood decontamination protocol [11,14]. Due to the
high selectivity indexes for both parasite forms, DB1965 moved to
in vivo studies of acute T. cruzi experimental infection. Since acute
toxicity studies showed side effects at doses $30 mg/kg via ip,
different protocols were performed using non-toxic doses.
Administration of DB1965 by 5 and 10 daily consecutive doses
of 12.5 mg/kg gave similar efficacy as Bz. Also, DB1965 did not
induce alterations in CK and ALT plasma levels, as also
demonstrated by the use of another AIA, the DB766 [11] as well
as with other amidines [20,21]. The analysis by ECG showed that
DB1965 alone or associated to Bz did not revert cardiac electric
alterations induced by the parasite infection. However, although
DB1965 alone or in combination with Bz did not induce, under
the present studied therapy schemes, parasitological cure (evalu-
ated by parasitaemia negativation, hemocultive and PCR assays),
this AIA as well as the combined therapy suppressed the
parasitemia and provided 100% survival of the infected animals.
In fact, unpublished data from our group using the same
experimental model of acute T.cruzi infection (Swiss male mice
infected with 10
4 bloodstream trypomastigotes of Y strain) showed
that no parasitological cure could be reached (hemocultive and
PCR analysis performed at the 30 day post treatment under
cyclophosphamide administration) after 20 daily consecutive doses
of 100 mg/kg Bz, (data not shown).
DB1831 is an analog of DB766, a AIA that presents high efficacy
against in vitro and in vivo experimental models of T.cruzi [11] and
Leishmania [16] infections but showing low activity against Besnoitia
besnoiti in vitro [25]. Although AIAs also contain amidine groups, they
havelowerpKa valuesand thus aremorehydrophobic thanclassical
AD since in AIAs an amidine nitrogen atom is bound to an aromatic
unit [26]. DB766 (IC50=60 nM against bloodstream forms) is a
modified version of furamidine (DB75) that only displays a moderate
anti-T.cruzi effect against bloodstream forms (IC50=16mM) [27]
confirmingthatsmallmodificationsofthechemicalstructureofthese
synthetic compounds can lead to a higher selectivity and efficacy. In
DB766, the 2 core structure-benzene rings of DB75 were altered
through the addition of two iso-propoxy groups, leading to superior
effect against intracellular trypanosomatid parasites like Leishmania
[16,26] and T.cruzi[11,15].Similarly,DB1831 and its mesylate form
(DB1965) also have high anti-T.cruzi activity and selectivity in vitro
and in vivo. The only difference in structure between DB766 and
DB1831 is the terminal groups (pyridine and pyrimidine, respec-
tively); which suggests that both pyrimidine and pyridine units in
these systemsare advantageous for T.cruziactivityandmeritsfurther
investigation. Although treatment with 12.5 mg/kg of DB1965 for
10 days suppressed the parasitaemia and gave 90% protection
against mortality, due to the detection of some undesirable sides
effects (like hyperactivity), longer periods of therapy (.10 daily
consecutive doses) were not performed and a combined treatment of
5 mg/kg DB1965+50 mg/kg Bz (sub-optimal dose) was chosen
following a protocol previously established [15]. When comparing
the efficacy of DB766 and DB1965 our data demonstrated that this
later AIAwas notaseffective invivo as DB766,especiallybyp.oroute
[11]. Since in mouse models, DB766 yields NOAEL values of
400 mg/kg for both p.o and ip routes [11], DB1965 seems to be less
well tolerated. As above briefly discussed, the difference in toxicity
between DB766 and DB1965, like the difference in efficacy, must be
attributed to the difference interminal groups.Further investigations
are required to sort out the effect of this small structural change on
both efficacy and toxicity. It is important to note that histopatho-
logical and biochemical data gave no major signals of toxicity for
DB1965 in the different schemes of treatment employed, using doses
up to 100 mg/kg via p.o and 25 mg/kg via ip.
The present report shows the promising in vitro and in vivo activity
of arylimidamides like DB1965 against T. cruzi infection and
validates further exploration of AIAs as new candidate for Chagas
disease therapy. In fact, although DB1965 did not produce
parasitological cure rates, its ability to reduce parasite burden and
to yield high protection against mortality highlights the efficacy of
these AIAs against T.cruzi. These results are encouraging because
Chagas disease is commercially an unattractive field for the
pharmaceutical industry despite a lack of therapeutic options other
than Bz and NF whose short comings are well known [28–30].
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